Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | NOS2 | P35228 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.32 |
| ▸ | GABRP | O00591 | 2/20 | 0.30 |
| ▸ | GABRD | O14764 | 2/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.30 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.30 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.30 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.30 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.30 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.30 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.30 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.30 |
| ▸ | GABRE | P78334 | 2/20 | 0.30 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9810240 | 1.00 | SMN1; SMN2 (0.34) | SMN1; SMN2HIF1ANOS1NOS2NOS3 | |
| SCHEMBL9326098 | 0.88 | KIF11 (0.36) | NOS1NOS2NOS3SLC7A5 | |
| SCHEMBL10422578 | 0.88 | KIF11 (0.36) | NOS1NOS2NOS3SLC7A5 | |
| SCHEMBL441158 | 0.84 | ALOX15 (0.42) | — | |
| SCHEMBL10421342 | 0.82 | SLC7A5 (0.47) | SMN1; SMN2HIF1AGRM2GRM3SLC7A5 | |
| SCHEMBL9810245 | 0.80 | DPP4 (0.36) | — | |
| SCHEMBL30863909 | 0.79 | CYP1A2 (0.36) | SMN1; SMN2HIF1AGRM2GRM3GABRP | |
| SCHEMBL8475144 | 0.74 | — | — | |
| SCHEMBL27527294 | 0.74 | — | — | |
| SCHEMBL8820876 | 0.74 | GRM2 (0.34) | NOS1NOS2NOS3GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110418837-B | Culture medium comprising oligopeptides | 赢创运营有限公司 | 2024-04-02 | — | — | CN | disclosed |
| EP-3372671-B1 | CULTURE MEDIUM COMPRISING OLGOPEPTIDES | EVONIK OPERATIONS GMBH (DE) | 2021-11-03 | — | — | EP | disclosed |
| EP-1144613-B2 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2020-05-06 | — | — | EP | disclosed |
| WO-2018162346-A1 | CULTURE MEDIUM COMPRISING OLIGOPEPTIDES | EVONIK TECHNOCHEMIE GMBH (DE) | 2018-09-13 | — | — | WO | disclosed |
| EP-3372671-A1 | CULTURE MEDIUM COMPRISING OLGOPEPTIDES | Evonik Technochemie GmbH (DE) | 2018-09-12 | — | — | EP | disclosed |
| US-20170362626-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2017-12-21 | — | — | US | disclosed |
| US-20160244798-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. | 2016-08-25 | — | — | US | disclosed |
| EP-2305804-B1 | MonoPEGylated human growth hormone | BOLDER BIOTECHNOLOGY INC (US) | 2015-05-06 | — | — | EP | disclosed |
| US-8957023-B2 | Methods for making proteins containing free cysteine residues | BOLDER BIOTECHNOLOGY INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8932828-B2 | Method for preparing recombinant granulocyte colony stimulating factor cysteine muteins | BOLDER BIOTECHNOLOGY, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20040018586-A1 | Lysis, denaturing, reducing Growth hormones | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-29 | — | — | US | disclosed |
| EP-1284987-A2 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | Bolder Biotechnology, Inc. (US) | 2003-02-26 | — | — | EP | disclosed |
| EP-1144613-A4 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC (US) | 2002-10-29 | — | — | EP | disclosed |
| WO-2001087925-A2 | METHODS FOR REFOLDING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY, INC. (US) | 2001-11-22 | — | — | WO | disclosed |
| EP-1144613-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | Bolder Biotechnology, Inc. (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000042175-A1 | METHODS FOR MAKING PROTEINS CONTAINING FREE CYSTEINE RESIDUES | BOLDER BIOTECHNOLOGY INC. (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0264953-B1 | USE OF N,N'-BIS-L-AMINO ACID-L-CYSTIN PEPTIDES IN AMINO ACID PREPARATIONS FOR ORAL AND PARENTERAL ADMINISTRATION | PFRIMMER KABI GMBH & CO. KG (DE) | 1991-05-08 | — | — | EP | disclosed |
| US-4968696-A | CHRONIC UREMIA OR HEPATIC CIRRHOSIS | PFRIMMER + CO. PHARMAZEUTISCHE WERKE ERLANGEN GMBH + CO. KG (DE) | 1990-11-06 | — | — | US | disclosed |
| WO-1988003150-A2 | N,N'-BIS-AMINO ACID-L-CYSTINE-PEPTIDE-CONTAINING AMINO ACID PREPARATIONS FOR ORAL AND PARENTERAL ADMINISTRATION | PFRIMMER + CO. PHARMAZEUTISCHE WERKE ERLANGEN GMBH (DE) | 1988-05-05 | — | — | WO | disclosed |
| EP-0264953-A2 | Use of N,N'-bis-L-amino acid-L-cystin peptides in amino acid preparations for oral and parenteral administration | PFRIMMER KABI GMBH & CO. KG (DE) | 1988-04-27 | — | — | EP | disclosed |